PubRank

Marcel Spaargaren

Author PubWeight™ 34.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012 4.17
2 Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 2004 2.46
3 Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007 1.92
4 Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008 1.79
5 Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013 1.69
6 Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002 1.50
7 Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007 1.31
8 Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2005 1.16
9 Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. Eur J Biochem 2002 1.13
10 Primary follicular lymphoma of the small intestine: alpha4beta7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B cells. Am J Pathol 2003 1.11
11 Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. Blood 2011 1.01
12 Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 2004 0.99
13 Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma. FEBS J 2013 0.95
14 The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta 2010 0.94
15 Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 2008 0.92
16 c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol 2002 0.92
17 Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PLoS One 2012 0.91
18 Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 2009 0.90
19 The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood 2008 0.89
20 Tubular epithelial syndecan-1 maintains renal function in murine ischemia/reperfusion and human transplantation. Kidney Int 2012 0.87
21 Impaired lymphoid organ development in mice lacking the heparan sulfate modifying enzyme glucuronyl C5-epimerase. J Immunol 2010 0.87
22 Stimulated plasmacytoid dendritic cells impair human T-cell development. Blood 2006 0.85
23 CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. PLoS One 2013 0.83
24 Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochem Biophys Res Commun 2002 0.83
25 The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral. J Immunol 2007 0.83
26 WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer. Biochem Biophys Res Commun 2010 0.81
27 Follicular dendritic cells catalyze hepatocyte growth factor (HGF) activation in the germinal center microenvironment by secreting the serine protease HGF activator. J Immunol 2005 0.81
28 R-Ras alters Ca2+ homeostasis by increasing the Ca2+ leak across the endoplasmic reticular membrane. J Biol Chem 2003 0.79
29 N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica 2011 0.78
30 Instant conditional transgenesis in the mouse hematopoietic compartment. J Immunol Methods 2008 0.76